Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01187043 · ClinicalTrials.gov registry record · Phase 1
Determination of the Lowest, Safe and Effective Dose of Proellex
A Phase 1 study, sponsored by Repros Therapeutics.
- Completed
- Registry status
- Phase 1
- Development phase
- 52
- Enrollment target
NCT01187043 is a Phase 1 study that has completed, run by Repros Therapeutics. The registered enrollment target is 52 participants.
The verdict
NCT01187043, a Phase 1 study, has completed, sponsored by Repros Therapeutics.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 52 participants
- Enrollment target
Study Summary
The purpose of this study is to determine the effects of five different doses of Proellex on menses, ovulation, liver function, and steady state exposure in women of reproductive age.
Interventions
- DRUG Proellex
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 52 participants |
| Start Date | 2010-08 |
| Est. Completion | 2012-03 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01187043
The ClinicalTrials.gov registry entry for NCT01187043 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 52 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Repros Therapeutics, which has 50 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Proellex is the first listed.
NCT01187043 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01187043 about?
NCT01187043 is a clinical study titled "Determination of the Lowest, Safe and Effective Dose of Proellex". The purpose of this study is to determine the effects of five different doses of Proellex on menses, ovulation, liver function, and steady state exposure in women of reproductive age.
What is the current status of trial NCT01187043?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 52 participants. The study started on 2010-08. Estimated completion is 2012-03.
What interventions are being tested in trial NCT01187043?
The interventions under investigation include: Proellex (DRUG).
Who is sponsoring clinical trial NCT01187043?
This trial is sponsored by Repros Therapeutics, which has 50 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.